Bruker (BRKR) Competitors

Agilent Technologies has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.9%. Bruker pays an annual dividend of $0.20 per share and has a dividend yield of 0.4%. Agilent Technologies pays out 22.5% of its earnings in the form of a dividend. Bruker pays out -83.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has increased its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Agilent Technologies had 17 more articles in the media than Bruker. MarketBeat recorded 20 mentions for Agilent Technologies and 3 mentions for Bruker. Bruker's average media sentiment score of 0.86 beat Agilent Technologies' score of 0.66 indicating that Bruker is being referred to more favorably in the news media.

87.4% of Agilent Technologies shares are owned by institutional investors. Comparatively, 79.5% of Bruker shares are owned by institutional investors. 0.2% of Agilent Technologies shares are owned by company insiders. Comparatively, 27.2% of Bruker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Agilent Technologies has a net margin of 18.26% compared to Bruker's net margin of -0.65%. Agilent Technologies' return on equity of 24.49% beat Bruker's return on equity.

Agilent Technologies currently has a consensus target price of $162.40, suggesting a potential upside of 40.20%. Bruker has a consensus target price of $50.54, suggesting a potential upside of 7.21%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Agilent Technologies is more favorable than Bruker.

Agilent Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Bruker has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Bruker has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Bio-Rad Laboratories has lower revenue, but higher earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Bio-Rad Laboratories has a net margin of 6.52% compared to Bruker's net margin of -0.65%. Bruker's return on equity of 11.60% beat Bio-Rad Laboratories' return on equity.

79.5% of Bruker shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bruker currently has a consensus price target of $50.54, suggesting a potential upside of 7.21%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential downside of 0.09%. Given Bruker's stronger consensus rating and higher possible upside, equities analysts clearly believe Bruker is more favorable than Bio-Rad Laboratories.

In the previous week, Bio-Rad Laboratories had 4 more articles in the media than Bruker. MarketBeat recorded 7 mentions for Bio-Rad Laboratories and 3 mentions for Bruker. Bruker's average media sentiment score of 0.86 beat Bio-Rad Laboratories' score of -0.33 indicating that Bruker is being referred to more favorably in the media.

IQVIA has a net margin of 8.33% compared to Bruker's net margin of -0.65%. IQVIA's return on equity of 30.50% beat Bruker's return on equity.

Bruker currently has a consensus price target of $50.54, indicating a potential upside of 7.21%. IQVIA has a consensus price target of $225.69, indicating a potential upside of 37.01%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Bruker.

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

In the previous week, IQVIA had 3 more articles in the media than Bruker. MarketBeat recorded 6 mentions for IQVIA and 3 mentions for Bruker. Bruker's average media sentiment score of 0.86 beat IQVIA's score of 0.70 indicating that Bruker is being referred to more favorably in the media.

79.5% of Bruker shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bruker has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

In the previous week, Bruker had 2 more articles in the media than Mettler-Toledo International. MarketBeat recorded 3 mentions for Bruker and 1 mentions for Mettler-Toledo International. Bruker's average media sentiment score of 0.86 beat Mettler-Toledo International's score of 0.00 indicating that Bruker is being referred to more favorably in the media.

Bruker has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

79.5% of Bruker shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 27.2% of Bruker shares are held by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bruker presently has a consensus price target of $50.54, suggesting a potential upside of 7.21%. Mettler-Toledo International has a consensus price target of $1,408.55, suggesting a potential upside of 28.20%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Bruker.

Mettler-Toledo International has a net margin of 21.40% compared to Bruker's net margin of -0.65%. Bruker's return on equity of 11.60% beat Mettler-Toledo International's return on equity.